Pay in 4 interest-free payments of $5.76 Learn more
Ships within 48 hours · Estimated delivery Nov 1 - Nov 6
FDA also announced on April 30, 2026 that it proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list
A 2022 cohort study analyzed weight loss outcomes in 175 people with obesity or overweight who were taking 1.7 mg or 2.4 mg of semaglutide for six months
FDA approval for obstructive sleep apnea In December 2024, the FDA approved tirzepatide (marketed as Zepbound) for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity
Its the only GLP-1 medication approved to slow the progression of kidney disease and reduce the risk of cardiovascular death in patients with type 2 diabetes and chronic kidney disease
US$ 22.99
US$ 22.65
US$ 28.42
US$ 29.80
